Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Collaborators: First Affiliated Hospital of Wenzhou Medical University; Peking Union Medical College Hospital; RenJi Hospital; Sir Run Run Shaw Hospital; The Central Hospital of Lishui City; The First Affiliated Hospital of Zhejiang Chinese Medical University
• Treatments: Rifaximin

Criteria

Inclusion Criteria:

• 18-75 years old;

• in line with the diagnostic criteria of diarrhea-type irritable bowel syndrome Roman IV；

• blood routine, blood biochemistry, stool examination and colonoscopy within 2 years are no problem;

• no intestinal warning symptoms

Exclusion Criteria:

• suffering from severe heart, lung, liver, kidney, nervous system diseases;

• suffering from mental disorders caused by schizophrenia, brain organic and physical diseases;

• suffering from other diseases that may affect intestinal function (such as diabetes, thyroid disease);

• History of previous abdominal surgery (excluding history of cholecystectomy or appendectomy);

• pregnant or lactating women;

• have undergone colonoscopy in the past month or accept other bowel preparation operations;

• In the past 1 month, have used antibiotics, antidiarrheal agents, intestinal flora regulation, Chinese medicine and other drugs;

• have participated in other dietary treatments;

• understand communication barriers, unable to communicate